XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Consolidated Statements of Operations        
Revenues $ 37,297 $ 18,530 $ 107,380 $ 52,397
Cost of revenues 20,189 4,529 56,776 13,129
Gross profit 17,108 14,001 50,604 39,268
Operating expenses:        
Sales and marketing 11,848 11,877 35,715 35,820
General and administrative 11,077 7,436 36,364 19,540
Research and development 1,504 2,416 4,918 6,999
Total operating expenses 24,429 21,729 76,997 62,359
Loss from operations (7,321) (7,728) (26,393) (23,091)
Other (income) expense:        
Interest expense 2,206 1,725 6,097 5,529
Loss on extinguishment of debt   4,427   4,427
Other income, net (126) (539) (561) (2,001)
Net loss (9,401) (13,341) (31,929) (31,046)
Less: Net loss attributable to non-controlling interest (356)   (89)  
Net loss attributable to Neuronetics stockholders' $ (9,045) $ (13,341) $ (31,840) $ (31,046)
Net loss per share of common stock outstanding, basic attributable to Neuronetics stockholders' $ (0.13) $ (0.44) $ (0.49) $ (1.04)
Net loss per share of common stock outstanding, diluted attributable to Neuronetics stockholders' $ (0.13) $ (0.44) $ (0.49) $ (1.04)
Weighted average common shares outstanding, basic (in shares) 67,309 30,267 65,006 29,931
Weighted average common shares outstanding, diluted (in shares) 67,309 30,267 65,006 29,931